Saliva-Based Pregnancy Tests Expand to Eight Markets
A new partnership brings fast, non-invasive testing to more households across Europe and beyond.
Updated on Oct. 28, 2026 in Pregnancy
Live Poll
Would you prefer a saliva-based pregnancy test over traditional urine-based testing for your home use?
VIORA and BioTeke have formed a partnership to manufacture and distribute non-invasive, saliva-based pregnancy tests. The new diagnostic tool is designed to provide results in just 20 seconds, with an initial rollout planned for eight international markets.
Why it matters
This partnership aims to meet growing consumer demand for less invasive pregnancy testing alternatives to traditional urine-based methods. By combining manufacturing capabilities with expanded distribution networks, the companies hope to improve access to quick, at-home diagnostics.
The saliva-based test provides results in 20 seconds, a significant speed improvement over standard home testing kits. The agreement covers exclusive commercial rights across 8 international markets.
The players
VIORA
A health technology firm focused on developing commercialization strategies and distribution channels for consumer diagnostics.
BioTeke
A biotechnology manufacturer that specializes in medical device technology and large-scale product production.
The details
The test functions by analyzing a saliva sample rather than requiring a urine sample, offering a more convenient experience for users. BioTeke is handling the manufacturing at its facilities, while VIORA coordinates the global commercialization strategy through retail, wholesale, and e-commerce channels. The companies are currently finalizing packaging and supply chain logistics to prepare for the commercial rollout.
Timeline
October 21, 2026: The companies signed a formal partnership expansion agreement.
October 2026: VIORA leadership conducted an on-site visit to BioTeke manufacturing facilities.
November 16-19, 2026: The partners will showcase the technology at the MEDICA 2026 exhibition in Germany.
The Home Front
This development marks a significant move in the shifting landscape of consumer-facing diagnostic tools. It follows a broader industry trend of prioritizing non-invasive, high-speed testing options that aim to replace traditional home-testing standards.
If you are interested in non-invasive diagnostic alternatives, keep an eye on upcoming retail pharmacy releases as the product begins its rollout. Consult your primary healthcare provider if you have questions regarding the reliability of new saliva-based testing methods versus conventional tests.
The takeaway
The move toward saliva-based diagnostic tools signals a shift in how families can perform private, quick health checks at home. Prospective users should monitor official brand announcements for regional availability, as these tests are expected to arrive in eight markets following the MEDICA 2026 event.
Further reading
For more on diagnostic options, visit our guide on Pregnancy.
More information
To see the upcoming release plans, you can Schedule a meeting at MEDICA 2026 directly.
Source note: This article includes information reported by Greatreporter -.
Live Poll
Would you prefer a saliva-based pregnancy test over traditional urine-based testing for your home use?
